Rapid Dose Therapeutics Corp. Files Patent Application for Lidocaine Oral Thin Strip
Rapid Dose Therapeutics Corp. (CSE: DOSE) has filed a patent application for its Lidocaine Oral Thin Film Strip with the Canadian Intellectual Property Office. The innovative product offers an alternative to traditional dental anesthesia methods, delivering lidocaine through a dissolvable strip that adheres to oral mucosa.
The Lidocaine QuickStrip™ provides precise application, complete dissolution, and efficient absorption. It can be used for various dental applications, including pre-procedure anesthesia and post-operative pain control. The product aims to reduce patient anxiety and save dentists' chair time by eliminating the traditional needle administration process, which typically takes up to five minutes with conventional methods.
Rapid Dose Therapeutics Corp. (CSE: DOSE) ha presentato una domanda di brevetto per la sua Lidocaine Oral Thin Film Strip presso l'Ufficio canadese della proprietà intellettuale. Questo prodotto innovativo offre un'alternativa ai metodi tradizionali di anestesia dentale, rilasciando lidocaina attraverso uno striscia dissolvibile che si aderisce alla mucosa orale.
La Lidocaine QuickStrip™ offre un'applicazione precisa, una completa dissoluzione e un'assorbimento efficiente. Può essere utilizzata per varie applicazioni dentali, inclusa l'anestesia pre-procedura e il controllo del dolore post-operatorio. Il prodotto mira a ridurre l'ansia dei pazienti e a risparmiare tempo ai dentisti, eliminando il tradizionale processo di somministrazione con ago, che solitamente richiede fino a cinque minuti con i metodi convenzionali.
Rapid Dose Therapeutics Corp. (CSE: DOSE) ha presentado una solicitud de patente para su Lidocaine Oral Thin Film Strip ante la Oficina Canadiense de Propiedad Intelectual. Este producto innovador ofrece una alternativa a los métodos tradicionales de anestesia dental, administrando lidocaína a través de una tira disoluble que se adhiere a la mucosa oral.
La Lidocaine QuickStrip™ proporciona una aplicación precisa, una disolución completa y una absorción eficiente. Puede utilizarse para diversas aplicaciones dentales, incluyendo anestesia previa al procedimiento y control del dolor postoperatorio. El producto tiene como objetivo reducir la ansiedad del paciente y ahorrar tiempo en la consulta dental, eliminando el proceso tradicional de administración con aguja, que normalmente toma hasta cinco minutos con los métodos convencionales.
Rapid Dose Therapeutics Corp. (CSE: DOSE)는 캐나다 지식재산청에 Lidocaine Oral Thin Film Strip의 특허 출원을 했습니다. 이 혁신적인 제품은 전통적인 치과 마취 방법에 대한 대안을 제공하며, 구강 점막에 부착되는 용해성 스트립을 통해 리도카인을 전달합니다.
Lidocaine QuickStrip™은 정확한 적용, 완전한 용해 및 효율적인 흡수를 제공합니다. 이는 치과의 다양한 용도, including 시술 전 마취 및 수술 후 통증 조절에 사용될 수 있습니다. 이 제품은 환자의 불안을 줄이고, 전통적인 주사 방법으로 인해 소요되는 최대 5분의 시간을 절약하여 치과 의사들의 치료 시간을 절약하는 것을 목표로 하고 있습니다.
Rapid Dose Therapeutics Corp. (CSE: DOSE) a déposé une demande de brevet pour son Lidocaine Oral Thin Film Strip auprès de l'Office canadien de la propriété intellectuelle. Ce produit innovant propose une alternative aux méthodes traditionnelles d'anesthésie dentaire, en libérant de la lidocaïne via une bande dissoute qui adhère à la muqueuse buccale.
La Lidocaine QuickStrip™ permet une application précise, une dissolution complète et une absorption efficace. Elle peut être utilisée pour diverses applications dentaires, y compris l'anesthésie préalable aux interventions et le contrôle de la douleur post-opératoire. Ce produit vise à réduire l'anxiété des patients et à faire gagner du temps aux dentistes en éliminant le processus d'administration traditionnel par aiguille, qui prend généralement jusqu'à cinq minutes avec les méthodes conventionnelles.
Rapid Dose Therapeutics Corp. (CSE: DOSE) hat einen Patentantrag für ihren Lidocaine Oral Thin Film Strip beim kanadischen Amt für geistiges Eigentum eingereicht. Das innovative Produkt bietet eine Alternative zu traditionellen zahnmedizinischen Anästhesieverfahren, indem es Lidocain über einen löslichen Streifen abgibt, der an der Mundschleimhaut haftet.
Der Lidocaine QuickStrip™ ermöglicht eine präzise Anwendung, vollständige Auflösung und effiziente Absorption. Er kann für verschiedene zahnmedizinische Anwendungen eingesetzt werden, einschließlich Anästhesie vor dem Eingriff und postoperative Schmerzbehandlung. Das Produkt zielt darauf ab, die Angst der Patienten zu verringern und die Behandlungszeit der Zahnärzte zu verkürzen, indem der traditionelle Injektionsprozess, der normalerweise bis zu fünf Minuten mit herkömmlichen Methoden dauert, entfällt.
- Patent application filed for new dental anesthesia delivery technology
- Product offers multiple applications in dental procedures and pain management
- Technology potentially reduces procedure time compared to traditional methods
- Complete dissolution eliminates equipment interference issues
- None.
Burlington, Ontario--(Newsfile Corp. - December 5, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian biotechnology company, is pleased to announce that it has filed a patent application for its Lidocaine Oral Thin Film Strip, with the Canadian Intellectual Property Office ("CIPO").
Dentists commonly perform dental procedures using anesthesia administered through injection by needle, which is commonly preceded by a spray, gel, jelly, cream, or ointment. RDT is proud to announce a significant breakthrough in the form of Thin Film Strip for oral use.
Using dissolvable films allows dentists to place an oral lidocaine strip directly to the treatment area with enhanced precision, delivering anesthetic by reliably adhering to the oral mucosa upon contact. When the film dissolves, the lidocaine is held directly onto the area of interest by the mucoadhesive film components, ensuring maximum effectiveness. This pleasantly flavored strip has the ability not only to deliver a pain-free dental procedure but also helps reduce patient anxiety prior to the introduction of a local anesthetic. The Lidocaine Strip doesn't clog the suction tubes as it dissolves completely and is absorbed into the oral mucosa. In many cases, treatment can be effectively solely performed with the Lidocaine QuickStrip™ for rapid application and pain relief.
The strength of the Lidocaine QuickStrip™ can vary for other dental uses such a post-op pain control for surgery, stomatitis, oral lesion, painful oral ulcers, and traumatic injuries.
The versatility of Lidocaine QuickStrip™ offers numerous advantages for both patients and practitioners. Developed and designed to reduce patient anxiety, The Lidocaine Strip boasts strong efficacy especially for patients who may feel nervous during dental visits. With its ease of administration, Lidocaine QuickStrip™ saves chair time for dentists—reducing the traditional needle administration process, which can take up to five minutes with conventional sprays and gels.
"Lidocaine QuickStrip™ presents a cost-effective and scalable solution for the dental industry, and this patent application marks a significant advancement in our innovative QuickStrip™ Oral Thin Film drug delivery platform," stated Mark Upsdell, CEO of RDT. "We are advancing through R&D milestones to develop a diverse array of applications leveraging QuickStrip™ technology, aiming to enhance RDT's impact and set a new benchmark for patient comfort and making a meaningful difference in dentistry."
About Rapid Dose Therapeutics Corp.
Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company's flagship product QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient. For more information about the Company, visit www.rapid-dose.com.
Contacts:
Mark Upsdell, CEO
416-477-1052
RDT Investor Contact:
Investor Relations
investorrealtions@rapid-dose.com
416-477-1052
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:
Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "intend", "may", "should", "anticipate", "expect", "potential", "believe", "intend", "will", "could", "are planned to", "are expected to" or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip™ product delivery method, the generation of recurring revenues, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/232705
FAQ
What is the new patent application filed by Rapid Dose Therapeutics (RDTCF)?
How does the Lidocaine QuickStrip technology by RDTCF work?
What are the main advantages of RDTCF's Lidocaine QuickStrip for dental procedures?
